Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Area of Science:

• Medical Oncology
• Clinical Trials
• Thoracic Surgery

Background:

• Recent trials indicate overall survival (OS) benefits from postoperative cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC).
• Identifying specific patient subgroups or treatment strategies that maximize this benefit is crucial for optimizing adjuvant therapy.

Purpose of the Study:

• To evaluate the impact of postoperative cisplatin-based chemotherapy on OS in patients with resected NSCLC.
• To identify patient characteristics and treatment variations associated with differential chemotherapy benefits.

Main Methods:

• Pooled individual patient data from five large trials (4,584 patients) of cisplatin-based chemotherapy in resected NSCLC.
• Analysis of interactions between patient subgroups, treatment types, and chemotherapy's effect on OS using hazard ratios (HRs) and log-rank tests.

Main Results:

• Overall, chemotherapy demonstrated a significant OS benefit (HR = 0.89; P = .005), translating to a 5.4% absolute 5-year survival advantage.
• Chemotherapy benefit varied significantly by stage, with higher efficacy observed in earlier stages (IA, IB) compared to later stages (II, III).
• Chemotherapy effect was more pronounced in patients with better performance status and did not significantly interact with sex, age, histology, surgical approach, or radiotherapy plans.

Conclusions:

• Postoperative cisplatin-based chemotherapy offers a significant survival improvement for patients diagnosed with non-small-cell lung cancer.
• The study highlights the importance of considering disease stage and performance status when administering adjuvant chemotherapy to NSCLC patients.